[Effects of Renal Function Evaluation with or without Serum Creatinine Adjustment on Cisplatin/Fluorouracil Therapy for Cervical Cancer].
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers
/ blood
Chemoradiotherapy
Cisplatin
/ administration & dosage
Creatinine
/ blood
Female
Fluorouracil
/ administration & dosage
Humans
Kidney Diseases
/ chemically induced
Kidney Function Tests
/ methods
Metabolic Clearance Rate
Middle Aged
Quality of Life
Uterine Cervical Neoplasms
/ drug therapy
cervical cancer
chemotherapy
cisplatin
creatinine clearance
renal function evaluation
side effect
Journal
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
ISSN: 1347-5231
Titre abrégé: Yakugaku Zasshi
Pays: Japan
ID NLM: 0413613
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
5
10
2019
pubmed:
5
10
2019
medline:
11
3
2020
Statut:
ppublish
Résumé
The dosage of cisplatin is adjusted according to creatinine clearance (Ccr) estimated by the Cockcroft-Gault formula, which is commonly used as a marker for renal function. It is known that different serum creatinine (Scr) levels are reported depending on the analytical methods utilized such as the Scr level by the enzyme method being lower than that by the Jaffe method. Although the enzyme method is used in Japan, most drug dosages, including cisplatin, are adjusted according to the estimated Ccr using the Jaffe method-based Scr level. The purpose of this study was to investigate whether assessment of renal function with or without Scr adjustment affects cisplatin-based chemotherapy in cervical cancer patients. The patients were divided into two groups, normal (Ccr≥60 mL/min with adjusted Scr) and false normal (Ccr<60 mL/min with adjusted Scr, but Ccr≥60 mL/min with non-adjusted Scr). The false normal group had significantly higher rates of cisplatin dose reduction after the second course than the normal group (p<0.05). Leukocytopenia and Grade 2 or higher neutropenia were significantly more common in the false normal group than in the normal group (p<0.05). These results suggest that evaluation of renal function using the adjusted Scr is important for the accurate dosage of cisplatin and that it helps to improve the patient's quality of life. Further investigations may provide useful information for accurate and safe cisplatin-based chemotherapy for cancer patients.
Identifiants
pubmed: 31582618
doi: 10.1248/yakushi.19-00114
doi:
Substances chimiques
Biomarkers
0
Creatinine
AYI8EX34EU
Cisplatin
Q20Q21Q62J
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
jpn
Sous-ensembles de citation
IM